Anabiosis Medsciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 03-01-2025
- Paid Up Capital ₹ 1.00 Cr
as on 03-01-2025
- Company Age 9 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.84 Cr
as on 03-01-2025
- Satisfied Charges ₹ 6.00 Cr
as on 03-01-2025
- Revenue -7.89%
(FY 2022)
- Profit -12.91%
(FY 2022)
- Ebitda -5.09%
(FY 2022)
- Net Worth -39.54%
(FY 2022)
- Total Assets -26.08%
(FY 2022)
About Anabiosis Medsciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹3.84 Cr. The company has closed loans amounting to ₹6.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Rajiv Bhargav, Ronak Surendra, Dishank Soni, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230GJ2015PTC084113
- Company No.
084113
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Aug 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Gandhi Nagar, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Anabiosis Medsciences?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajiv Bhargav  | Director | 19-Dec-2020 | Current |
| Ronak Surendra | Director | 19-Dec-2020 | Current |
| Dishank Soni | Director | 06-Aug-2015 | Current |
| Maulish Shah | Director | 19-Dec-2020 | Current |
Financial Performance of Anabiosis Medsciences.
Anabiosis Medsciences Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 7.89% decrease. The company also saw a substantial fall in profitability, with a 12.91% decrease in profit. The company's net worth observed a substantial decline by a decrease of 39.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Anabiosis Medsciences?
In 2021, Anabiosis Medsciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Yes Bank Limited Creation Date: 25 Aug 2021 | ₹3.84 Cr | Open |
Others Creation Date: 30 Aug 2016 | ₹6.00 Cr | Satisfied |
How Many Employees Work at Anabiosis Medsciences?
Anabiosis Medsciences has a workforce of 28 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Anabiosis Medsciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Anabiosis Medsciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
